Monday, July 14, 2008

Asif tests positive

In a statement issued by the BCCI, IPL commissioner Lalit Modi, who had on Sunday indicated that the player in question was a subcontinental pacer, confirmed Asif's name.

The Indian Premier League compared the result from the WADA-approved laboratory in Switzerland with the data collected by IDTM, the Sweden based independent agency which organised the anti-dope testing in accordance with World Anti-Doping Agency (WADA) standards, the statement said.

It was also checked if Asif had applied for and was granted a Therapeutic Use Exemption (TUE). It was found that Asif had not applied for a TUE. A note in writing has been sent to the player and his home board and to the franchisee on the findings.

The player has been informed that the specimen supplied by him has revealed an Adverse Analytical Finding and he has the right to request that the 'B' Sample (supplied by him at the same time as the A Sample which has revealed said Adverse Analytical Finding) be analysed.

If Asif requests for his 'B' sample to be analysed, he and his representative along with an IPL representative will have the right to attend the opening and analysis of it.

Once the results of the same are obtained it will be referred to the IPL Drug Tribunal, which consists of former Indian captain Sunil Gavaskar, Dr Ravi Bapat (former Vice Chancellor of Maharashtra University of Health Sciences) and Shirish Gupte, a leading lawyer.

The Tribunal will in due course follow the procedure as laid down in the Anti-Doping policy.

In a related development, it has been learnt that the announcement of Pakistan's 30-man list of probables for the Champions Trophy, which was to be revealed Monday, has been delayed by another day.

This is not the first time that Asif has been held guilty of drug abuse. In 2006, both Asif and team mate Shoaib Akhtar were found to have taken the banned steroid nandrolone after failing an internal PCB drug test. The PCB handed the players bans of one and two years respectively, which were overturned on appeal.

No comments: